natgillin/translations-raw huggingface dataset:
5 It is essential for patients with pre-existing or gestational diabetes to maintain good metabolic control throughout pregnancy.
Nujno je, da bolnice z obstoječim ali gestacijskim diabetesom vso nosečnost vzdržujejo dobro presnovno urejenost.
Insulin Human Winthrop Rapid can be used during breastfeeding.
Zdravilo Insulin Human Winthrop Rapid je med dojenjem dovoljeno uporabljati.
Lactating women may require adjustments in insulin dose and diet.
Pri doječih ženskah utegne biti potrebna prilagoditev odmerka insulina in prehrane.
The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a result of visual impairment.
5 Bolnikova zmožnost koncentracije in reagiranja se lahko poslabša zaradi hipoglikemije ali hiperglikemije, pa tudi npr. zaradi prizadetosti vida.
This may constitute a risk in situations where these abilities are of special importance (e. g. driving a car or operating machinery).
To je lahko nevarno v okoliščinah, v katerih sta ti zmožnosti posebno pomembni (npr. pri vožnji avta ali upravljanju s stroji).
It should be considered whether it is advisable to drive or operate machinery in these circumstances.
V takšnih okoliščinah je treba razmisliti, ali je priporočljivo, da bolnik vozi ali upravlja s stroji.
Hypoglycaemia, in general the most frequent undesirable effect of insulin therapy, may occur if the insulin dose is too high in relation to the insulin requirement.
Pojavi se, če je odmerek insulina prevelik glede na potrebo po insulinu.
In clinical trials and during marketed use, the frequency varies with patient population and dose regimens.
V kliničnih preskušanjih in med marketinško uporabo se je pogostnost razlikovala glede na populacijo bolnikov in sheme odmerjanja.
The following related adverse reactions from clinical investigations are listed below by system organ class and in order of decreasing incidence: very common (≥ 1/ 10); common (≥ 1/ 100, < 1/ 10); uncommon (≥ 1/ 1,000, < 1/ 100); rare (≥ 1/ 10,000, < 1/ 1,000); very rare (< 1/ 10,000), not known (cannot be estimated from the available data).
Naslednji neželeni učinki iz kliničnih raziskav, povezani z uporabo zdravila, so našteti spodaj po organskih sistemih in upadajoči pogostnosti: zelo pogosti (≥ 1/ 10), pogosti (≥ 1/ 100, < 1/ 10), občasni (≥ 1/ 1. 000, < 1/ 100), redki (≥ 1/ 10. 000, < 1/ 1. 000), zelo redki (< 1/ 10. 000), ni znano (ni mogoče oceniti iz razpoložljivih podatkov).
Uncommon: shock Not known: immediate type allergic reactions (hypotension, angioneurotic oedema, bronchospasm, generalised skin reactions), anti-insulin antibodies
Občasni: šok Ni znano: takojšnje alergijske reakcije (hipotenzija, angionevrotični edem, bronhospazem, generalizirane kožne reakcije), protitelesa proti insulinu
In rare cases, the presence of such anti-insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency to hyper- or hypoglycaemia.
V redkih primerih je zaradi prisotnosti takšnih protiteles proti insulinu treba prilagoditi odmerek insulina, da bi odpravili nagnjenost k hiper - ali hipoglikemiji.
6 Metabolism and nutrition disorders
Presnovne in prehranske motnje
Common: oedema Not known: sodium retention
Pogosti: edemi Ni znano: zastajanje natrija
Not known: proliferative retinopathy, diabetic retinopathy, visual impairment
Ni znano: proliferativna retinopatija, diabetična retinopatija, okvara vida
Long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy.
6 Dolgoročno izboljšanje glikemične urejenosti zmanjša nevarnost za napredovanje diabetične retinopatije.
Not known: lipodystrophy
Ni znano: lipodistrofija
As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin absorption.
Tako kot pri zdravljenju z vsakim insulinom se lahko na mestu injiciranja pojavi lipodistrofija, ki upočasni lokalno absorpcijo insulina.
Common: injection site reactions Uncommon: injection site urticaria Not known: injection site inflammation, injection site swelling, injection site pain, injection site pruritus, injection site erythema.
Pogosti: reakcije na mestu injiciranja Občasni: urtikarija na mestu injiciranja Ni znano: vnetje na mestu injiciranja, oteklost na mestu injiciranja, bolečina na mestu injiciranja, srbenje na mestu injiciranja, eritem na mestu injiciranja.
Adjustments in dosage of the medicinal product, meal patterns, or physical activity may be needed.
Potrebne utegnejo biti prilagoditve odmerka zdravila, razporeda obrokov ali telesne dejavnosti.
More severe episodes with coma, seizure, or neurologic impairment may be treated with intramuscular/ subcutaneous glucagon or concentrated intravenous glucose.
Hujše primere s komo, epileptiformnimi napadi ali nevrološko prizadetostjo je mogoče zdraviti z glukagonom intramuskularno ali subkutano oz. s koncentrirano glukozo intravensko.
Antidiabetic agent.
Zdravila za zdravljenje diabetesa.
Insulins and analogues, fast-acting, ATC Code:
Insulini s hitrim delovanjem in analogi, oznaka ATC:
- lowers blood glucose and promotes anabolic effects as well as decreasing catabolic effects,
- znižuje glukozo v krvi, spodbuja anabolne učinke in zmanjšuje katabolne učinke,
- increases the transport of glucose into cells as well as the formation of glycogen in the muscles
- zvečuje transport glukoze v celice, nastajanje glikogena v mišicah in jetrih in izboljšuje izrabo
and the liver, and improves pyruvate utilisation.
piruvata.
- increases lipogenesis in the liver and adipose tissue and inhibits lipolysis,
- zvečuje lipogenezo v jetrih in maščevju in zavira lipolizo,
- promotes the uptake of amino acids into cells and promotes protein synthesis,
- spodbuja privzem aminokislin v celice in spodbuja sintezo beljakovin,
- enhances the uptake of potassium into cells.
- zvečuje vstopanje kalija v celice.
Pharmacodynamic characteristics
Farmakodinamične značilnosti
Insulin Human Winthrop Rapid is an insulin with rapid onset and short duration of action.
7 Insulin Human Winthrop Rapid je insulin s hitrim začetkom in kratkim trajanjem delovanja.
Concerning mixing or incompatibility with other insulins see section 6.6.
Glede mešanja in inkompatibilnosti z drugimi insulini glejte poglavje 6. 6.
Shelf life after first use of the vial:
Rok uporabnosti po prvi uporabi viale:
The product may be stored for a maximum of 4 weeks not above 25°C away from direct heat or direct light.
Zdravilo lahko shranjujete največ 4 tedne pri temperaturi do 25 °C zaščiteno pred neposredno toploto ali svetlobo.
Store in a refrigerator (2°C - 8°C).
Neodprte viale Shranjujte v hladilniku (2 °C - 8 °C).
Opened vials:
Odprte viale
For storage precautions, see section 6.3.
8 Za navodila za shranjevanje glejte poglavje 6. 3.
5 ml solution in a vial (type 1 colourless glass) with a flanged cap (aluminium), a stopper (chlorobutyl rubber (type 1)) and a tear-off cap (polypropylene).
5 ml raztopina v viali (iz brezbarvnega stekla tipa 1) s prirobljeno zaporko (iz aluminija), z zamaškom (iz klorobutilne gume (tipa 1)) in zaporko, ki se odtrga (iz polipropilena).
As with all insulin preparations, Insulin Human Winthrop Rapid must not be mixed with solutions containing reducing agents such as thioles and sulphites.
Tako kot velja za vse pripravke insulinov, tudi zdravila Insulin Human Winthrop Rapid ne smete mešati z raztopinami, ki vsebujejo reducente, npr. tiole ali sulfite.
It must also be remembered that neutral regular insulin precipitates out at a pH of approximately 4.5 to 6.5.
Zavedati se je treba, da nevtralni navadni insulin precipitira v območju pH približno od 4, 5 do 6, 5.
Insulin Human Winthrop Rapid may be mixed with all Sanofi-Aventis human insulins, but NOT with those designed specifically for use in insulin pumps.
Insulin Human Winthrop Rapid se sme mešati z vsemi humanimi insulini, ki jih izdeluje Sanofi - Aventis, NE pa s tistimi, ki so posebej pripravljeni za uporabo v insulinskih črpalkah.
Insulin Human Winthrop rapid must also NOT be mixed with insulins of animal origin or with insulin analogues.
Zdravila Insulin Human Winthrop Rapid prav tako NE smete mešati z insulini živalskega izvora ali insulinskimi analogi.
Insulins of different concentration (e. g.
Insulinov različne koncentracije (npr.
100 IU per ml and 40 IU per ml) must not be mixed.
100 i. e. / ml in 40 i. e. / ml) se ne sme mešati.
Insulin Human Winthrop Rapid 40 IU/ ml solution for injection in a vial
Insulin Human Winthrop Rapid 40 i. e. / ml raztopina za injiciranje v viali
Each ml contains 40 IU insulin human (equivalent to 1.4 mg).
En mililiter vsebuje 40 i. e. humanega insulina (kar ustreza 1. 4 mg).
Each vial contains 10 ml of solution for injection, equivalent to 400 IU insulin.
Vsaka viala vsebuje 10 ml raztopine za injiciranje, kar ustreza 400 i. e. insulina.
11 Transfer to Insulin Human Winthrop Rapid
Prehod na Insulin Human Winthrop Rapid
Dosage adjustment may be necessary when transferring patients from one insulin preparation to another.
Pri prehodu bolnika z enega insulinskega pripravka na drugega utegne biti potrebna prilagoditev odmerjanja.
Insulin Human Winthrop Rapid contains 40 IU of insulin per ml solution.
En mililiter raztopine Insulin Human Winthrop Rapid vsebuje 40 i. e. insulina.
Only injection syringes designed for this strength of insulin (40 IU per ml) are to be used.
Uporabljati se sme le injekcijske brizge, namenjene za to koncentracijo insulina (40 i. e. / ml).
4.4 Special warnings and precautions for use
11 4. 4 Posebna opozorila in previdnostni ukrepi
13 Adherence of the patient to the dosage and dietary regimen, correct insulin administration and awareness of hypoglycaemia symptoms are essential to reduce the risk of hypoglycaemia.
Za zmanjšanje nevarnosti hipoglikemije mora bolnik nujno upoštevati shemo odmerjanja in načrt prehrane, pravilno aplicirati insulin in poznati simptome hipoglikemije.
14 Lactation
Dojenje
The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a result of visual impairment.
13 Bolnikova zmožnost koncentracije in reagiranja se lahko poslabša zaradi hipoglikemije ali hiperglikemije, pa tudi npr. zaradi prizadetosti vida.
15 Eyes disorders
Očesne bolezni
Long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy.
14 Dolgoročno izboljšanje glikemične urejenosti zmanjša nevarnost za napredovanje diabetične retinopatije.
16 Mode of action
Način delovanja
Pharmacodynamic characteristics
15 Farmakodinamične značilnosti
17 Shelf life after first use of the vial:
Rok uporabnosti po prvi uporabi viale:
For storage precautions, see section 6.3.
16 Odprte viale Za navodila za shranjevanje glejte poglavje 6. 3.
10 mlsolution in a vial (type 1 colourless glass) with a flanged cap (aluminium), a stopper (chlorobutyl rubber (type 1)) and a tear-off cap (polypropylene).
10 ml raztopina v viali (iz brezbarvnega stekla tipa 1) s prirobljeno zaporko (iz aluminija), z zamaškom (iz klorobutilne gume (tipa 1)) in s pokrovčkom, ki se odtrga (iz polipropilena).
Insulin Human Winthrop Rapid must also NOT be mixed with insulins of animal origin or with insulin analogues.
Zdravila Insulin Human Winthrop Rapid prav tako NE smete mešati z insulini živalskega izvora ali insulinskimi analogi.
17 January 2007
21. januarja 2007
Insulin Human Winthrop Rapid 100 IU/ ml solution for injection in a cartridge
Insulin Human Winthrop Rapid 100 i. e. / ml raztopina za injiciranje v vložku
Each cartridge contains 3 ml of solution for injection, equivalent to 300 IU insulin.
Vsak vložek vsebuje 3 ml raztopine za injiciranje, kar ustreza 300 i. e. insulina.
Human insulin is produced by recombinant DNA technology in Escherichia coli.
Humani insulin Insulin Human Winthrop je pridobljen s tehnologijo rekombinantne DNA iz bakterij Escherichia coli.
20 Transfer to Insulin Human Winthrop Rapid
Prehod na Insulin Human Winthrop Rapid
Insulin Human Winthrop Rapid in cartridges has been developed for use in the OptiPen series.
Insulin Human Winthrop Rapid v vložkih je pripravljen za uporabo v injekcijskih peresnikih OptiPen.
21 4.4 Special warnings and precautions for use
4. 4 Posebna opozorila in previdnostni ukrepi
Patients hypersensitive to Insulin Human Winthrop Rapid for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
19 Bolniki, ki so preobčutljivi za Insulin Human Winthrop Rapid, a tudi nobenega drugega pripravka ne prenašajo bolje, smejo zdravljenje nadaljevati le pod skrbnim zdravniškim nadzorom in – če je potrebno – ob hkratnem antialergijskem zdravljenju.
Adherence of the patient to the dosage and dietary regimen, correct insulin administration and awareness of hypoglycaemia symptoms are essential to reduce the risk of hypoglycaemia.
Za zmanjšanje nevarnosti hipoglikemije mora bolnik nujno upoštevati shemo odmerjanja in načrt prehrane, pravilno aplicirati insulin in poznati simptome hipoglikemije.
23 4.7 Effects on ability to drive and use machines
4. 7 Vpliv na sposobnost vožnje in upravljanja s stroji
Patients should be advised to take precautions to avoid hypoglycaemia whilst driving.
21 Bolnikom je treba svetovati, naj upoštevajo ustrezne varnostne ukrepe, da bi se izognili hipoglikemiji med upravljanjem vozila.
24 A marked change in glycaemic control may cause temporary visual impairment, due to temporary alteration in the turgidity and refractive index of the lens.
Izrazita sprememba glikemične urejenosti lahko prehodno poslabša vid zaradi prehodno spremenjenega turgorja in lomnega količnika indeksa leče.
Skin and subcutaneous tissue disorders
22 Bolezni kože in podkožja
25 Mode of action
Način delovanja
Insulin Human Winthrop Rapid is an insulin with rapid onset and short duration of action.
23 Insulin Human Winthrop Rapid je insulin s hitrim začetkom in kratkim trajanjem delovanja.
The cartridge in-use (in the insulin pen) or carried as a spare may be stored for a maximum of 4 weeks not above 25°C away from direct heat or direct light.
Rok uporabnosti po prvi uporabi vložka Vložek, ki ga uporabljate (v insulinskem injekcijskem peresniku) ali ga imate pri sebi za rezervo, lahko shranjujete največ 4 tedne pri temperaturi do 25 °C zaščiteno pred neposredno toploto ali svetlobo.
Store in a refrigerator (2°C - 8°C).
Neodprti vložki Shranjujte v hladilniku (2 °C - 8 °C).
In-use cartridges:
24 Vložki, ki jih uporabljate.
For storage precautions, see section 6.3.
Za navodila za shranjevanje glejte poglavje 6. 3.
3 ml solution in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
3 ml raztopina v vložku (iz brezbarvnega stekla tipa 1) z batom (iz brombutilne gume (tipa 1)) in prirobljeno zaporko (iz aluminija) z zamaškom (iz brombutilne ali laminata poliizoprenske in brombutilne gume (tipa 1)).
Insulin pen The cartridges are to be used in conjunction with an insulin pen such as OptiPen and other pens suitable for Insulin Human Winthrop cartridges and as recommended in the information provided by the device manufacturer.
Vložki se uporabljajo skupaj z insulinskim injekcijskim peresnikom kot je OptiPen in drugimi primernimi injekcijskimi peresniki za vložke Insulin Human Winthrop in po navodilih izdelovalca injekcijskega peresnika.
The manufacturer’ s instructions for using the pen must be followed carefully for loading the cartridge, attaching the injection needle, and administering the insulin injection.
Dosledno upoštevajte izdelovalčeva navodila za uporabo injekcijskega peresnika glede nameščanja vložka in injekcijske igle ter injiciranja insulina.
If the pen malfunctions (see instructions for using the pen), the solution may be drawn from the cartridge into an injection syringe (suitable for an insulin with 100 IU/ ml) and injected.
Če se injekcijski peresnik pokvari (glejte navodila za uporabo injekcijskega peresnika), je mogoče raztopino potegniti iz vložka z injekcijsko brizgo (primerno za insulin s 100 i. e. / ml) in injicirati.
Cartridges Before insertion into the pen, Insulin Human Winthrop Rapid must be kept at room temperature for 1 to 2 hours.
Pred vstavitvijo v injekcijski peresnik mora biti Insulin Human Winthrop Rapid 1 do 2 uri na sobni temperaturi.
27 Mixing of insulins
Mešanje insulinov
17 January 2007
17. januarja 2007
Insulin Human Winthrop Rapid 100 IU/ ml solution for injection in a pre-filled pen.
Insulin Human Winthrop Rapid 100 i. e. / ml raztopina za injiciranje v napolnjenem injekcijskem peresniku
Each pen contains 3 ml of solution for injection, equivalent to 300 IU insulin.
Vsak injekcijski peresnik vsebuje 3 ml raztopine za injiciranje, kar ustreza 300 i. e. insulina.
Clear, colourless solution of water-like consistency.
Raztopina je bistra, brezbarvna vodi podobne konsistence.
OptiSet delivers insulin in increments of 2 IU up to a maximum single dose of 40 IU.
Z injekcijskim peresnikom Insulin Human WinthropOptiSet je mogoče odmerek nastavljati v stopnjah po 2 i. e. do največjega posamičnega odmerka 40 i. e.
29 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
27 Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
30 In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
28 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
31 Handling of the pen
29 Ravnanje z injekcijskim peresnikom
32 4.8 Undesirable effects
4. 8 Neželeni učinki
33 As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin absorption.
31 Tako kot pri zdravljenju z vsakim insulinom se lahko na mestu injiciranja pojavi lipodistrofija, ki upočasni lokalno absorpcijo insulina.
More severe episodes with coma, seizure, or neurologic impairment may be treated with intramuscular/ subcutaneous glucagon or concentrated intravenous glucose.
Hujše primere s komo, epileptiformnimi napadi ali nevrološko prizadetostjo je mogoče zdraviti z glukagonom intramuskularno ali podkožno oz. s koncentrirano glukozo intravensko.
34 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
In healthy subjects, the serum half-life of insulin is approximately 4 to 6 minutes.
32 Pri zdravih osebah je razpolovni čas insulina v serumu približno 4 do 6 minut.
The pen in-use or carried as a spare may be stored for a maximum of 4 weeks not above 25°C away from direct heat or direct light.
Rok uporabnosti po prvi uporabi injekcijskega peresnika Injekcijski peresnik, ki ga uporabljate ali ga imate pri sebi za rezervo, lahko shranjujete največ 4 tedne pri temperaturi do 25 °C zaščiteno pred neposredno toploto ali svetlobo.
Store in a refrigerator (2°C - 8°C).
Injekcijski peresniki, ki jih ne uporabljateShranjujte v hladilniku (2 °C - 8 °C).
For storage precautions, see section 6.3.
Injekcijski peresniki, ki jih uporabljate Za navodila za shranjevanje glejte poglavje 6. 3.
35 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
3 ml solution in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
3 ml raztopina v vložku (iz brezbarvnega stekla tipa 1), z batom (iz brombutilne gume (tipa 1)) ter s prirobljeno zaporko (iz aluminija) z zamaškom (iz brombutilne ali laminata poliizoprenske in
36 Handling of the pen The Instructions for Use included in the Package Leaflet must be read carefully before using OptiSet.
34 Ravnanje z injekcijskim peresnikom Pred uporabo OptiSeta natančno preberite navodila za ravnanje z OptiSetom v navodilu za uporabo.
Schematic diagram of the pen
telo peresnika igla peresnika (ni priložena)
Only use needles that are compatible for use with OptiSet. • Always perform the safety test before each injection. • If a new OptiSet is used the initial safety test must be done with the 8 units preset by the manufacturer. • The dosage selector can only be turned in one direction. • Never turn the dosage selector (change the dose) after injection button has been pulled out. • This pen is only for the patients use.
Uporabljajte le igle, primerne za uporabo z OptiSetom. • Pred vsakim injiciranjem opravite varnostni preizkus. • Če uporabljate nov OptiSet, morate prvi varnostni preizkus narediti z odmerkom 8 enot, ki ga je nastavil že izdelovalec. • Izbirnik odmerka je mogoče vrteti le v eno smer. • Ko je gumb za injiciranje izvlečen, izbirnika odmerka ne smete več obračati (tj. ne smete več spreminjati odmerka). • Ta injekcijski peresnik uporabljajte samo vi.
It must not be shared with anyone else. • If the injection is given by another person, special caution must be taken by this person to avoid accidental needle injury and transmission of infection. • Never use OptiSet if it is damaged or if you are not sure that it is working properly. • Always have a spare OptiSet in case your OptiSet is lost or damaged.
Ne delite ga z nikomer drugim. • Če vam injekcijo da druga oseba, je treba posebej paziti, da se ta oseba po naključju ne poškoduje z iglo in da ne prenese okužbe. • Ne uporabljajte OptiSeta, če je poškodovan ali če niste prepričani, da deluje pravilno. • Vedno imejte na zalogi rezerven OptiSet, če injekcijski peresnik izgubite ali se ta poškoduje.
Please check section 6.4 of this leaflet for instructions on how to store OptiSet.
Navodila za shranjevanje injekcijskega peresnika OptiSet boste našli v poglavju 6. 4 teh navodil.
You can clean the outside of your OptiSet by wiping it with a damp cloth.
Zunanjost svojega injekcijskega peresnika OptiSet lahko čistite z vlažno krpo.
Do not soak, wash or lubricate the pen as this may damage it.
Ne namakajte, umivajte ali podmazujte injekcijskega peresnika, ker se zaradi tega lahko pokvari.
If you are concerned that your OptiSet may be damaged, use a new one.
Če vas skrbi, da je vaš injekcijski peresnik morda pokvarjen, uporabite novega.
Check the Insulin
Preverjanje insulina
The appearance of insulin should also be checked: the insulin solution must be clear, colourless, with no solid particles visible, and must have a water-like consistency.
Prav tako je treba preveriti izgled insulina: raztopina insulina mora biti čista, brezbarvna, brez vidnih delcev in vodi podobne 35 konsistence.
Do not use this OptiSet if insulin is cloudy, coloured or has particles.
Ne uporabite tega injekcijskega peresnika OptiSet, če je insulin moten, obaravan ali so v njem delci.
37 Step 2.
Korak 2.
In-use OptiSet, select a dose of 2 units by turning the dosage selector forward till the dose arrow points to 2.
Pri OptiSetu, ki ga uporabljate, izberite odmerek 2 enoti tako, da izbirnik odmerka zavrtite naprej, dokler odmerna puščica ne pokaže 2.
If still no insulin comes out, change the needle, as it might be blocked and try again.
Če insulin še vedno ne pride ven, zamenjajte iglo, saj je morda zamašena in poskusite znova.
The injection button allows checking the actual loaded dose.
36 Gumb za injiciranje omogoča preverjanje dejansko napolnjenega odmerka.
38 Step 6.
Korak 6.
This ensures that the full dose of insulin has been delivered.
To zagotovi, da dobite celoten odmerek insulina.
Remove and discard the needle
Odstranite in zavrzite iglo
This helps prevent contamination and/ or infection as well as entry of air into the insulin reservoir and leakage of insulin, which can cause inaccurate dosing.
To pomaga preprečiti onesnaženje in/ ali okužbo, pa tudi vstopanje zraka v rezervoar z insulinom in iztekanje insulina, kar lahko povzroči nenatančno odmerjanje..